Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01192412




Registration number
NCT01192412
Ethics application status
Date submitted
30/08/2010
Date registered
1/09/2010
Date last updated
11/01/2017

Titles & IDs
Public title
The CHIPS Trial (Control of Hypertension In Pregnancy Study)
Scientific title
The CHIPS Trial (Control of Hypertension In Pregnancy Study)
Secondary ID [1] 0 0
MCT-87522
Secondary ID [2] 0 0
H08-00882
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Gestational Hypertension 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Hypertension

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Surgery - Intervention is blood pressure management approach
Treatment: Surgery - Intervention is blood pressure management approach.

Active comparator: 'Less tight' control. - The diastolic blood pressure (dBP) treatment goal is 100 mmHg.

Active comparator: 'Tight' control. - The diastolic blood pressure (dBP) treatment goal is 85 mmHg.


Treatment: Surgery: Intervention is blood pressure management approach
1) 'Less tight' control. The dBP treatment goal is 100 mmHg. For safety, if dBP is \>105 mmHg, then antihypertensive medication must be started or increased in dose. For dBP \<100 mmHg, antihypertensive therapy should be decreased in dose or stopped, as appropriate. The intervention will be applied until delivery.

Treatment: Surgery: Intervention is blood pressure management approach.
'Tight' control. The dBP treatment goal is 85 mmHg. For safety, if dBP is \<80 mmHg, then antihypertensive medication must be decreased in dose or discontinued. If dBP is \>85 mmHg, then antihypertensive therapy should be started or increased in dose. The intervention will be applied until delivery.
Intervention code [1] 0 0
Treatment: Surgery
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Pregnancy Loss or NICU Admission for Greater Than 48 Hours
Timepoint [1] 0 0
6 weeks
Secondary outcome [1] 0 0
Serious Maternal Complications Measured up to 6 Weeks Postpartum
Timepoint [1] 0 0
6 weeks

Eligibility
Key inclusion criteria
1. Pre-existing or gestational hypertension (pre-existing hypertension is dBP greater than or equal to 90 mmHg before pregnancy or 20 weeks' gestation; gestational hypertension is dBP greater than or equal to 90 mmHg that develops after 20 weeks)
2. dBP of 90 - 105 mmHg if NOT TAKING antihypertensive therapy, or dBP of 85 - 105 mmHg if TAKING antihypertensive therapy
3. Live foetus (confirmed by Doptone assessment of foetal heart tones within one week before randomisation)
4. Gestational age 14 - 33+6 weeks (as measured by last menstrual period or dating ultrasound)
Minimum age
No limit
Maximum age
No limit
Sex
Females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Severe systolic hypertension (defined as a systolic blood pressure [sBP] greater than or equal to 160 mmHg at randomisation)
2. Proteinuria (defined as greater than or equal to 0.3 g/d by 24 hour urine collection, or if a 24 hour urine collection is not available, by a urinary protein:creatinine ratio of greater than or equal to 30 mg/mmol or urinary dipstick of greater than or equal to 2+)
3. Use of an angiotensin converting enzyme (ACE) inhibitor at greater than or equal to 14+0 weeks' gestation
4. Contraindication to either arm of the trial or to pregnancy prolongation
5. Known multiple gestation
6. Known lethal or major foetal anomaly
7. Plan to terminate pregnancy
8. Prior participation in CHIPS

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
NA
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/04/2009
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/02/2014
Sample size
Target
Accrual to date
Final
987
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
Campbelltown Hospital - Campbelltown
Recruitment hospital [2] 0 0
Liverpool Hospital - Liverpool
Recruitment hospital [3] 0 0
Women's and Children's Hospital - Adelaide
Recruitment hospital [4] 0 0
Ipswich Hospital - Ipswich
Recruitment hospital [5] 0 0
King Edward Memorial Hospital - Subiaco
Recruitment hospital [6] 0 0
St John of God Hospital - Subiaco
Recruitment postcode(s) [1] 0 0
- Campbelltown
Recruitment postcode(s) [2] 0 0
- Liverpool
Recruitment postcode(s) [3] 0 0
- Adelaide
Recruitment postcode(s) [4] 0 0
- Ipswich
Recruitment postcode(s) [5] 0 0
- Subiaco
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Connecticut
Country [2] 0 0
United States of America
State/province [2] 0 0
Kentucky
Country [3] 0 0
United States of America
State/province [3] 0 0
Massachusetts
Country [4] 0 0
United States of America
State/province [4] 0 0
Minnesota
Country [5] 0 0
United States of America
State/province [5] 0 0
New Jersey
Country [6] 0 0
United States of America
State/province [6] 0 0
North Carolina
Country [7] 0 0
United States of America
State/province [7] 0 0
Oregon
Country [8] 0 0
United States of America
State/province [8] 0 0
South Carolina
Country [9] 0 0
United States of America
State/province [9] 0 0
Wisconsin
Country [10] 0 0
Argentina
State/province [10] 0 0
Corrientes
Country [11] 0 0
Argentina
State/province [11] 0 0
Mendoza
Country [12] 0 0
Argentina
State/province [12] 0 0
Santa Fe
Country [13] 0 0
Argentina
State/province [13] 0 0
Tucuman
Country [14] 0 0
Brazil
State/province [14] 0 0
Goiania
Country [15] 0 0
Brazil
State/province [15] 0 0
Niteroi
Country [16] 0 0
Brazil
State/province [16] 0 0
Porto Alegre
Country [17] 0 0
Brazil
State/province [17] 0 0
Rio de Janeiro
Country [18] 0 0
Brazil
State/province [18] 0 0
Rio de Janerio
Country [19] 0 0
Brazil
State/province [19] 0 0
Sao Paulo
Country [20] 0 0
Canada
State/province [20] 0 0
Alberta
Country [21] 0 0
Canada
State/province [21] 0 0
British Columbia
Country [22] 0 0
Canada
State/province [22] 0 0
Manitoba
Country [23] 0 0
Canada
State/province [23] 0 0
Newfoundland and Labrador
Country [24] 0 0
Canada
State/province [24] 0 0
Nova Scotia
Country [25] 0 0
Canada
State/province [25] 0 0
Ontario
Country [26] 0 0
Canada
State/province [26] 0 0
Quebec
Country [27] 0 0
Canada
State/province [27] 0 0
Saskatchewan
Country [28] 0 0
Canada
State/province [28] 0 0
Regina
Country [29] 0 0
Chile
State/province [29] 0 0
Osorno
Country [30] 0 0
Chile
State/province [30] 0 0
Puente Alto
Country [31] 0 0
Colombia
State/province [31] 0 0
Cali
Country [32] 0 0
Estonia
State/province [32] 0 0
Tartu
Country [33] 0 0
Hungary
State/province [33] 0 0
Debrecen
Country [34] 0 0
Israel
State/province [34] 0 0
Bnei Brak
Country [35] 0 0
Israel
State/province [35] 0 0
Hadera
Country [36] 0 0
Israel
State/province [36] 0 0
Nazareth
Country [37] 0 0
Jordan
State/province [37] 0 0
Amman
Country [38] 0 0
Netherlands
State/province [38] 0 0
's-Hertogenbosch
Country [39] 0 0
Netherlands
State/province [39] 0 0
Almere
Country [40] 0 0
Netherlands
State/province [40] 0 0
Amersfoort
Country [41] 0 0
Netherlands
State/province [41] 0 0
Amsterdam
Country [42] 0 0
Netherlands
State/province [42] 0 0
Enschede
Country [43] 0 0
Netherlands
State/province [43] 0 0
Groningen
Country [44] 0 0
Netherlands
State/province [44] 0 0
Haarlem
Country [45] 0 0
Netherlands
State/province [45] 0 0
Hilversum
Country [46] 0 0
Netherlands
State/province [46] 0 0
Hoofddorp
Country [47] 0 0
Netherlands
State/province [47] 0 0
Maastricht
Country [48] 0 0
Netherlands
State/province [48] 0 0
Nieuwegein
Country [49] 0 0
Netherlands
State/province [49] 0 0
Oss
Country [50] 0 0
Netherlands
State/province [50] 0 0
Utrecht
Country [51] 0 0
Netherlands
State/province [51] 0 0
Veldhoven
Country [52] 0 0
Netherlands
State/province [52] 0 0
Zwolle
Country [53] 0 0
New Zealand
State/province [53] 0 0
Auckland
Country [54] 0 0
New Zealand
State/province [54] 0 0
Christchurch
Country [55] 0 0
Poland
State/province [55] 0 0
Gdansk
Country [56] 0 0
Poland
State/province [56] 0 0
Lodz
Country [57] 0 0
Poland
State/province [57] 0 0
Poznan
Country [58] 0 0
United Kingdom
State/province [58] 0 0
Basildon
Country [59] 0 0
United Kingdom
State/province [59] 0 0
Birmingham
Country [60] 0 0
United Kingdom
State/province [60] 0 0
Blackburn
Country [61] 0 0
United Kingdom
State/province [61] 0 0
Bradford
Country [62] 0 0
United Kingdom
State/province [62] 0 0
Chesterfield
Country [63] 0 0
United Kingdom
State/province [63] 0 0
Coventry
Country [64] 0 0
United Kingdom
State/province [64] 0 0
Derby
Country [65] 0 0
United Kingdom
State/province [65] 0 0
Halifax
Country [66] 0 0
United Kingdom
State/province [66] 0 0
Lancashire
Country [67] 0 0
United Kingdom
State/province [67] 0 0
Lancaster
Country [68] 0 0
United Kingdom
State/province [68] 0 0
Leicester
Country [69] 0 0
United Kingdom
State/province [69] 0 0
Liverpool
Country [70] 0 0
United Kingdom
State/province [70] 0 0
London
Country [71] 0 0
United Kingdom
State/province [71] 0 0
Manchester
Country [72] 0 0
United Kingdom
State/province [72] 0 0
Newcastle upon Tyne
Country [73] 0 0
United Kingdom
State/province [73] 0 0
Nottinghamshire
Country [74] 0 0
United Kingdom
State/province [74] 0 0
Nottingham
Country [75] 0 0
United Kingdom
State/province [75] 0 0
Ormskirk
Country [76] 0 0
United Kingdom
State/province [76] 0 0
Plymouth
Country [77] 0 0
United Kingdom
State/province [77] 0 0
Sheffield
Country [78] 0 0
United Kingdom
State/province [78] 0 0
Slough
Country [79] 0 0
United Kingdom
State/province [79] 0 0
Sunderland
Country [80] 0 0
United Kingdom
State/province [80] 0 0
Swansea
Country [81] 0 0
United Kingdom
State/province [81] 0 0
Warwickshire
Country [82] 0 0
United Kingdom
State/province [82] 0 0
Wolverhampton
Country [83] 0 0
United Kingdom
State/province [83] 0 0
York

Funding & Sponsors
Primary sponsor type
Other
Name
University of British Columbia
Address
Country
Other collaborator category [1] 0 0
Government body
Name [1] 0 0
Canadian Institutes of Health Research (CIHR)
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Other
Name [2] 0 0
Sunnybrook Research Institute
Address [2] 0 0
Country [2] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Laura A Magee, MD, FRCPC, MSc, FACP
Address 0 0
The University of British Columbia
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/study/NCT01192412